New development

April 2006
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1080
Academic Journal
The article focuses on the development of a new vaccine against influenza A subtype H5N1 or avian flu by Mary Holscher and colleagues. The vaccine is based on a nonreplicating human adenovirus that contains a gene from the H5N1 virus. They were able to grow the resulting vaccine in cell lines rather than in embryonated eggs. Evaluation of the safety of the vaccine in numerous clinical trials is mentioned.


Related Articles

  • Clinic Roundup.  // BioWorld Today;7/5/2011, Vol. 22 Issue 128, p7 

    The article presents an update on clinical trials in the pharmaceutical biotechnology industry. A Phase II/III trial of immunotherapy talactoferrin for severe sepsis has been launched by Agennix AG of Planegg, Germany. Axomadol has failed to meet predetermined efficacy endpoints in a Phase III...

  • Emory University to test vaccines against possible influenza pandemic.  // Infectious Disease News;Oct2008, Vol. 21 Issue 10, p19 

    The article reports on a clinical trial of a new avian influenza vaccine by the Emory Vaccine and Treatment Evaluation Unit by Emory University in Atlanta, Georgia, along with collaborators at the Mayo Clinic in Rochester, Minnesota. The trial will involve 500 healthy people who have not been...

  • Potential bird flu vaccine.  // Meat Trades Journal;12/7/2012, p2 

    The article reports on the research of the Pirbright Institute towards finding a vaccine against avian influenza which threatens the poultry sector and human health.

  • Don't Count Chickens Until They're Vaccinated. Breindl, Anette // BioWorld Today;12/17/2012, Vol. 23 Issue 243, Special section p2 

    The article focuses on a study published in the December 11, 2012 issue of "PLoS ONE" which examined the effect of vaccination on a strain of high-pathogenic avian influenza.

  • Bird Flu Vaccine Looks Promising. Elliott, William T. // Clinical Oncology Alert;Aug2008 Pharmacology Watch, p1 

    The article discusses research on a two-dose vaccine against avian flu. It references a study conducted by researchers from Baxter Bioscience, published in the volume 358 issue of the "New England Journal of Medicine." The researchers developed a whole-virus vaccine that was tested on 275...

  • In brief.  // BMJ: British Medical Journal (International Edition);3/6/2004, Vol. 328 Issue 7439, p540 

    Offers news briefs related to medicine as of March 6, 2004. Report that the U.S. National Institutes of Health halted the estrogen-only study of the women's health initiative because of the risk of stroke; Imminence of a human vaccine for avian influenza; Reference to a malpractice award...

  • Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells. Ingram, N.; MacCormac, L. P.; Oxley, N. T.; Burns, P. A.; Hall, G. D. // Cancer Gene Therapy;Oct2010, Vol. 17 Issue 10, p684 

    Adenovirus is the most frequently used virus in gene therapy clinical trials. There have been conflicting reports on the ability of adenovirus to transduce primary ovarian cancer samples and the expression of relevant cell surface molecules. These factors were examined using primary ovarian...

  • E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cheong, S. C.; Wang, Y.; Meng, J.-H.; Hill, R.; Sweeney, K.; Kirn, D.; Lemoine, N. R.; Halldén, G. // Cancer Gene Therapy;Jan2008, Vol. 15 Issue 1, p40 

    The majority of clinical trials evaluating replication-selective oncolytic adenoviruses utilized mutants with immunomodulatory E3B genes deleted, likely contributing to the attenuated efficacy. We investigated whether an intact immune response could contribute to the observed improved efficacy...

  • Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells. van den Hengel, Sanne K.; de Vrij, Jeroen; Uil, Taco G.; Lamfers, Martine L.; Smitt, Peter A. E. Sillevis; Hoeben, Rob C. // Virology Journal;2011, Vol. 8 Issue 1, p162 

    Background: The survival of glioma patients with the current treatments is poor. Early clinical trails with replicating adenoviruses demonstrated the feasibility and safety of the use of adenoviruses as oncolytic agents. Antitumor efficacy has been moderate due to inefficient virus replication...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics